Apotex Corporation

Generic pharmaceutical manufacturer

Based in FL

🤖

AI Overview

With $1.2M in lobbying spend across 30 quarterly filings, Apotex Corporation is a significant lobbying presence. Their lobbying covers 4 issue areas. Active from 2019 to 2025.

$1.2M

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2019	$180K
2020	$200K
2021	$200K
2022	$200K
2023	$200K
2024	$130K
2025	$80K

Issues Lobbied

Health Issues Budget/Appropriations Manufacturing Defense

Lobbying Firms

Government Counsel, LLC

Lobbyists

Henry Menn

Government Agencies Targeted

These are the government entities that Apotex Corporation disclosed contacting in their lobbying filings.

HOUSE OF REPRESENTATIVESSENATECommerce, Dept of (DOC)Council of Economic Advisers (CEA)Executive Office of the President (EOP)Health & Human Services, Dept of (HHS)Office of Management & Budget (OMB)

View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Budget/Appropriations, Manufacturing, Defense

Patient access to more affordable generic medicines.

President's Budget For A Better America (FY2020) relating to generic exclusivity

H.R. 1506-Fair And Immediate Release of Generic Drugs Act; H.R.1499-Protecting Consumer Access to Generic Drugs Act of 2019; H.R. 938-The Blocking Act of 2019.Implementation of Public Law 115-52, the

H.R. 1506-Fair And Immediate Release of Generic Drugs Act; H.R.1499-Protecting Consumer Access to Generic Drugs Act of 2019; H.R. 938-The Blocking Act of 2019. H.R. 987 - Strengthening Health Care and

H.R. 987-Strengthening Health Care and Lowering Prescription Drug Costs (Section 101);S. 1895-Lower Health Care Costs Act (Section 205); issues relating to pharmaceutical market blockages caused by pa